KURA Kura Oncology Inc.

19.55
+0.38  (+2%)
Previous Close 19.17
Open 19.38
Price To Book 4.99
Market Cap 746,507,894
Shares 38,184,547
Volume 359,285
Short Ratio
Av. Daily Volume 303,091

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2 additional data at EHA June 14, 2019. Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts.
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2 data due 2H 2019.
Tipifarnib
Head and neck squamous cell carcinomas (HNSCC)
Phase 1 data due 2019.
KO-947
Solid tumors
Phase 2 data due 2H 2019.
Tipifarnib - KO-TIP-001
Head and Neck Cancer With HRAS Mutations
Phase 1 trial to be initiated 2Q 2019.
KO-539
Relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)?
  2. What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)?
  3. Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  4. Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
  5. Kura Oncology Announces Commencement of Public Offering of Common Stock
  6. Company News For Jun 17, 2019
  7. Kura Oncology Soars After Lymphoma Treatment Test Results
  8. Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal
  9. Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
  10. Edited Transcript of KURA earnings conference call or presentation 7-May-19 8:30pm GMT
  11. Here’s What Hedge Funds Think About Kura Oncology, Inc. (KURA)
  12. Kura Oncology, Inc. (KURA) Q1 2019 Earnings Call Transcript
  13. Kura Oncology: 1Q Earnings Snapshot
  14. Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
  15. Kura Oncology to Report First Quarter 2019 Financial Results
  16. Edited Transcript of KURA earnings conference call or presentation 5-Mar-19 9:30pm GMT
  17. Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
  18. Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today's Competitive Landscape
  19. The Kura Oncology (NASDAQ:KURA) Share Price Has Soared 317%, Delighting Many Shareholders